A Phase 1/2 Study of HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, in Patients With Locally Advanced or Metastatic Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Gemcitabine (Primary) ; HLX 301 (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Carcinoma; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Shanghai Henlius Biotech

07 Aug 2023 Planned primary completion date changed from 1 Mar 2023 to 15 Sep 2023.
02 Feb 2023 Status changed from recruiting to completed.
02 Feb 2023 According to Henlius media release, the company announces the completion of this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com